CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome

Stefan Heinrichs; Jason N. Berman; Taylor M. Ortiz; Steven M. Kornblau; Donna S. Neuberg; Elihu H. Estey; A. Thomas Look

doi:10.1111/j.1365-2141.2005.05555.x

CD34⁺ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome

Stefan Heinrichs, Jason N. Berman, Taylor M. Ortiz, Steven M. Kornblau, Donna S. Neuberg, Elihu H. Estey, A. Thomas Look

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Overexpression of HOXA9 is linked to the molecular pathogenesis of acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), conferring a poor prognosis. HOXA9 expression levels were analysed in the diagnostic bone marrow (BM) samples of 13 MDS patients. HOXA9 was expressed by CD34⁺ BM cells at median levels 3.1-fold higher than in CD34^- cells from the same patient and at median levels 4.3-fold higher than in CD34⁺ cells from healthy donors. These results indicate that CD34⁺ cell selection is required to accurately assess the expression levels of HOXA9 and related genes in the multipotential malignant progenitor cells of MDS patients.

Original language	English
Pages (from-to)	83-86
Number of pages	4
Journal	British Journal of Haematology
Volume	130
Issue number	1
DOIs	https://doi.org/10.1111/j.1365-2141.2005.05555.x
State	Published - Jul 2005
Externally published	Yes

Keywords

CD34
HOX
Myelodysplastic syndrome

Access to Document

10.1111/j.1365-2141.2005.05555.x

Cite this

@article{9b96ff8f203c40628eeeabdd1d989bad,

title = "CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome",

abstract = "Overexpression of HOXA9 is linked to the molecular pathogenesis of acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), conferring a poor prognosis. HOXA9 expression levels were analysed in the diagnostic bone marrow (BM) samples of 13 MDS patients. HOXA9 was expressed by CD34+ BM cells at median levels 3.1-fold higher than in CD34- cells from the same patient and at median levels 4.3-fold higher than in CD34+ cells from healthy donors. These results indicate that CD34+ cell selection is required to accurately assess the expression levels of HOXA9 and related genes in the multipotential malignant progenitor cells of MDS patients.",

keywords = "CD34, HOX, Myelodysplastic syndrome",

author = "Stefan Heinrichs and Berman, {Jason N.} and Ortiz, {Taylor M.} and Kornblau, {Steven M.} and Neuberg, {Donna S.} and Estey, {Elihu H.} and Look, {A. Thomas}",

year = "2005",

month = jul,

doi = "10.1111/j.1365-2141.2005.05555.x",

language = "English",

volume = "130",

pages = "83--86",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome

AU - Heinrichs, Stefan

AU - Berman, Jason N.

AU - Ortiz, Taylor M.

AU - Kornblau, Steven M.

AU - Neuberg, Donna S.

AU - Estey, Elihu H.

AU - Look, A. Thomas

PY - 2005/7

Y1 - 2005/7

N2 - Overexpression of HOXA9 is linked to the molecular pathogenesis of acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), conferring a poor prognosis. HOXA9 expression levels were analysed in the diagnostic bone marrow (BM) samples of 13 MDS patients. HOXA9 was expressed by CD34+ BM cells at median levels 3.1-fold higher than in CD34- cells from the same patient and at median levels 4.3-fold higher than in CD34+ cells from healthy donors. These results indicate that CD34+ cell selection is required to accurately assess the expression levels of HOXA9 and related genes in the multipotential malignant progenitor cells of MDS patients.

AB - Overexpression of HOXA9 is linked to the molecular pathogenesis of acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), conferring a poor prognosis. HOXA9 expression levels were analysed in the diagnostic bone marrow (BM) samples of 13 MDS patients. HOXA9 was expressed by CD34+ BM cells at median levels 3.1-fold higher than in CD34- cells from the same patient and at median levels 4.3-fold higher than in CD34+ cells from healthy donors. These results indicate that CD34+ cell selection is required to accurately assess the expression levels of HOXA9 and related genes in the multipotential malignant progenitor cells of MDS patients.

KW - CD34

KW - HOX

KW - Myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=22144464507&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2005.05555.x

DO - 10.1111/j.1365-2141.2005.05555.x

M3 - Article

C2 - 15982348

AN - SCOPUS:22144464507

SN - 0007-1048

VL - 130

SP - 83

EP - 86

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1